Compass Pathways ($CMPS) is easily considered to be one of the leaders in the psychedelic sector. Earlier this week, they released their Q1 2022 earnings report.

Because Compass has a great deal of funding, they continue to have a massive amount of opportunities in front of them.

In the video below, we dig beyond solely the positive clinical trial results they’ve reported.

If you haven’t done so already, please like and subscribe the growing Psychedelic Invest YouTube channel.